Latest Views & News

Avacta makes some progress on missing the Covid boat – shares slide but valuation still bonkers

By Tom Winnifrith | Monday 23 November 2020


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Today, from AstraZeneca (AZN) and the City of lost causes, we have news on a third vaccine against Covid-19. There will soon be a fourth and a fifth and at some stage lots of folks will ignore concerns about potential long term side effects to get vaccinated against a disease which kills 0.05% of those under 70 who catch it. And a bedwetting world can breathe a sigh of relief and, even idiots like Matt Hancock, will realise that we will not need mass testing and we can get on with our lives.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

|